Podium to Practice: Chicago 2025 – GI: BREAKWATER

Podium to Practice: Chicago 2025 – GI: BREAKWATER

Podium to Practice: Chicago 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Sharlene Gill

Icon Chair Speaker

Speakers

Dr. Rachel Goodwin

Dr. Florian Lordick

Studies / Trials Discussed

LBA3500 – First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): Progression-free survival and updated overall survival analyses.

Studies/trials discussed:

LBA3500 – First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): Progression-free survival and updated overall survival analyses.
Tagged